Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT01918332

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01918332
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01918332. Randomized; triple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-12-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
Condition
Hypertension,
Condition
Hyperlipidemia
Intervention (Drug)
Valsartan 160mg
Intervention (Drug)
Rosuvastatin 20mg
Intervention (Drug)
Valsartan 160mg placebo
Intervention (Drug)
Rosuvastatin 20mg placebo
Lead sponsor
LG Life Sciences (class: industry)

Record details

Record id
cardio:ct-nct01918332
Content hash
d2868cc583d64ce8069be3b4af0d5c27a0a3e6b0dae2d64af45ce32b6b184510